The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Experimental testing initiated with WuXi AppTec

18 May 2020 07:00

RNS Number : 1267N
e-Therapeutics plc
18 May 2020
 

e-therapeutics PLC

 

COVID-19 update: experimental testing initiated with WuXi AppTec

 

 

Oxford, UK, 18 May 2020 - e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces the initiation of experimental testing on the first set of compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform. The Company will work with WuXi AppTec to perform the studies.

 

In line with our previous statement on the 23rd March 2020, we continue to pursue an NDD approach to identify approved and known drugs, both alone and as synergistic combinations, that could be rapidly repositioned for the treatment of COVID-19. Importantly, we are focusing on therapeutic strategies that target host systems, therefore minimising the risk of resistance and potentially being effective for the treatment of other viral conditions.

 

An initial compound set, which we believe has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.

 

 

Ali Mortazavi, Executive Chairman of e-therapeutics, commented: "I am pleased to report progress on our contribution to the fight against COVID-19, advancing from the computational stage of our project into experimental work. We are pursuing a multipronged effort for this project and will continue to provide updates as further data becomes available."

 

 

-Ends-

 

For more information, please contact:

 

e-therapeutics plc

Ali Mortazavi, Executive Chairman

 

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser) 

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000 

www.numis.com

 

FTI Consulting

Simon Conway/Stephanie Cuthbert

Tel: +44 (0) 203 727 1000

Email: e-therapeutics@fticonsulting.com

 

 

 About e-therapeutics

 

e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.

 

We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.

 

The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").

We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.

 

We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDBDLLFBELZBBX
Date   Source Headline
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding
8th Nov 201910:54 amRNSHolding(s) in Company
29th Oct 20194:10 pmRNSHolding(s) in Company
28th Oct 20192:36 pmRNSHolding(s) in Company
28th Oct 201912:05 pmRNSHolding(s) in Company
28th Oct 20198:00 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHalf-year Report
17th Sep 20194:41 pmRNSHolding(s) in Company
4th Sep 20192:05 pmRNSSecond Price Monitoring Extn
4th Sep 20192:00 pmRNSPrice Monitoring Extension
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
23rd Aug 201911:21 amRNSHolding(s) in Company
22nd Aug 201911:42 amRNSHolding(s) in Company
13th Aug 20197:00 amRNSe-therapeutics to work with top pharma company
1st Aug 20197:00 amRNSExtends Research Collaboration with Novo Nordisk
15th Jul 20192:06 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
2nd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 20192:06 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20193:17 pmRNSHolding(s) in Company
26th Jun 20194:41 pmRNSHolding(s) in Company
6th Jun 20193:58 pmRNSHolding(s) in Company
30th Apr 201911:21 amRNSResult of AGM
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
29th Mar 201910:00 amRNSDirector/PDMR Shareholding
20th Mar 201911:05 amRNSSecond Price Monitoring Extn
20th Mar 201911:00 amRNSPrice Monitoring Extension
14th Mar 201912:39 pmEQSEdison issues outlook on Jersey Electricity (JEL)
8th Mar 201910:30 amRNSNotice of Annual General Meeting and Annual Report
5th Mar 20193:51 pmEQSEdison issues update on e-Therapeutics (ETX)
5th Mar 20197:00 amRNSFull Year Results
20th Feb 20197:00 amRNSNotification of Full Year Results Date
3rd Jan 20199:00 amRNSDirector/PDMR Shareholding
12th Dec 20181:01 pmEQSEdison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)
10th Dec 20187:00 amRNSResearch Collaboration Agreement with Novo Nordisk
6th Dec 201810:36 amEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
6th Dec 20187:00 amRNSE-therapeutics and C4X Collaboration
29th Nov 20187:00 amRNSDrug Discovery Innovation Programme Presentation
12th Nov 201811:30 amRNSe-therapeutics to present at BioCentury Summit
5th Nov 20187:00 amRNSHolding(s) in Company
8th Oct 201810:42 amEQSEdison issues update on e-Therapeutics (ETX)
4th Oct 20187:00 amRNSInterim Results for six months ended 31 July 2018
17th Sep 201811:30 amRNSNotice of Interim Results
9th Aug 20187:00 amRNSDirector Shareholding
7th Aug 20187:00 amRNSDirector/PDMR Shareholding
3rd Jul 20182:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.